Nordihydroguaiaretic acid

| Cat. No.: | HY-N0198 | | |
|--------------------|---|-------|----------|
| CAS No.: | 500-38-9 | | |
| Molecular Formula: | $C_{18}H_{22}O_4$ | | |
| Molecular Weight: | 302.36 | | |
| Target: | Lipoxygenase; Autophagy; Ferroptosis | | |
| Pathway: | Metabolic Enzyme/Protease; Autophagy; Apoptosis | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

SOLVENT & SOLUBILITY

| In Vitro | DMSO : 250 mg/mL (826.83 mM; Need ultrasonic) | | | | | |
|----------|--|--|--------------------|------------|------------|--|
| | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | |
| | | 1 mM | 3.3073 mL | 16.5366 mL | 33.0732 mL | |
| | | 5 mM | 0.6615 mL | 3.3073 mL | 6.6146 mL | |
| | | 10 mM | 0.3307 mL | 1.6537 mL | 3.3073 mL | |
| | Please refer to the so | lubility information to select the app | propriate solvent. | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution | | | | | |
| | 3. Add each solvent o Solubility: ≥ 2.08 n | one by one: 10% DMSO >> 90% cor ng/mL (6.88 mM); Clear solution | n oil | | | |

| BIOLOGICAL ACTIVITY | | | | |
|---------------------------|---|--|--|--|
| Description | Nordihydroguaiaretic acid is a 5-lipoxygenase (5LOX) (IC $_{50}$ =8 $\mu\text{M})$ and tyrosine kinase inhibitor. | | | |
| IC ₅₀ & Target | 5-LOX 8 μΜ (IC ₅₀) | | | |
| In Vitro | The natural dicatechol Nordihydroguaiaretic acid (NDGA) is a selective 5LOX inhibitor from the creosote plant (Larrea tridentata: Zygophyllaceae). The 5LOX-inhibiting natural dicatechol Nordihydroguaiaretic acid is a very effective, non-toxic | | | |

,OH

ОН

Product Data Sheet

HO、

HO



| | antagonist of TNF α -stimulated microglial activation. Nordihydroguaiaretic acid is approximately six times more potent than Minocycline in vitro, with an IC ₅₀ value of 8±3 µM and no toxicity at 100 µM. Significant NO ₂ ⁻ suppression is observed at 800 nM Nordihydroguaiaretic acid. Similar efficacy is observed for natural and synthetic Nordihydroguaiaretic acid, as well as for the acetyl ester of Nordihydroguaiaretic acid. Nordihydroguaiaretic acid also suppresses TNF α -stimulated PGE ₂ production by EOC-20 cells with an IC ₅₀ of 841 nM ^[1] . To test the proliferation effect of prostaglandin E1 and Nordihydroguaiaretic acid (NDGA) on cancer cell lines, HepG2 cell lines are treated with various doses of the two compounds and the positive compounds 8-anilino-1-naphtalene sulfonate (ANS), respectively, for 24 h and cell viability is examined by the MTT assay. ANS displays a dose-dependent inhibition (0, 10, 30, 50, 80, 100, 120, and 150 µM) with the estimated IC ₅₀ being 25.888 µM. The tested IC ₅₀ of prostaglandin E1 is 41.223 µM and Nordihydroguaiaretic acid is 45.646 µM, respectively, at different concentrations of 0, 30, 60, 80, 100, 120, and 140 µM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
|---------|---|
| In Vivo | Compared with the control ob/ob chow diet group, there is a significant reduction of body weight starting from 9 wk treatment in the high-dose Nordihydroguaiaretic acid (NDGA) diet group, and from 12 wk in the low-dose group. Nordihydroguaiaretic acid treatment results in higher body (rectal) temperatures of ob/ob mice, especially with the high dose of Nordihydroguaiaretic acid ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| ΒΡΟΤΟCOL | |
|---|--|
| PROTOCOL | |
| Cell Assay ^[2] | MTT assay is used to measure cell growth-inhibitory activity of the selected most promising compounds in HepG2 cell lines. Cells are cultured in 96-well culture plate at 1×10 ⁴ cells/well. After 24 h cultured at 37 °C in the atmosphere of 5% CO ₂ , cells are adhered and treated with different concentrations of the targeted compounds (e.g., Nordihydroguaiaretic acid, 0, 30, 60, 80, 100, 120, and 140 µM) and incubated for 24 h. Then, the supernatants are discarded and MTT (0.5 mg/mL) is added to each well and incubated at 37°C in 5% CO ₂ for an additional 4 h. Following, the MTT is removed and 150 µL of formazan in DMSO is added to terminate response and then plates are set to the table shaker for 5 min at low speed. Cell proliferation is evaluated by measuring the absorbance at 570 nm using ELISA Plate Reader. The IC ₅₀ values are calculated by SPSS statistics 17.0 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Animal Administration ^[3] | Mice ^[3] Seven-week-old male control C57BL/6J mice, male leptin-deficient (<i>ob/ob</i>) mice, and male <i>Ppar</i> α-deficient mutant mice (B6.129S4-Pparatm1Gonz/J) are used. These mice are fed a standard chow diet for 1 wk to allow them to acclimatize to a controlled new environment (25±2°C, 55±5% relative humidity with a 12-h light-dark cycle). Subsequently, one group of ob/ob mice is switched to a chow diet supplemented with either low- (0.83 g/kg chow diet) or high-dose (2.5 g/kg chow diet) Nordihydroguaiaretic acid and maintained on this diet for 16 wk. The other groups of ob/ob mice and control mice continue to be fed a normal chow diet for 16 wk. In another set of studies, C57BL/6J mice and Pparα-deficient mutant mice are fed either a high-fat diet (~60% of total calories come from fat), or the same high-fat diet supplemented with a high dose of Nordihydroguaiaretic acid (2.5 g/kg diet). Food intake and body weights are measured once a week throughout the experiment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

- Adv Healthc Mater. 2023 Mar 5;e2202826.
- Biomed Pharmacother. 2020 Jul;127:110151.
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303.

REFERENCES

[1]. West M, et al. The arachidonic acid 5-lipoxygenase inhibitor Nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004 Oct;91(1):133-43.

[2]. Lu F, et al. Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine. Molecules. 2016 Sep 21;21(9). pii: E1259.

[3]. Zhang H, et al. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and independent pathways. Am J Physiol Gastrointest Liver Physiol. 2013 Jan 1;304(1):G72-86.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA